Group V secreted phospholipase A2 induces the release of proangiogenic and antiangiogenic factors by human neutrophils

Frontiers in Immunology

Volumn 8, Issue APR, 2017, Pages

  Loffredo, Stefania ^a   Borriello, Francesco ^a,b   Iannone, Raffaella ^a   Ferrara, Anne L ^a   Galdiero, Maria R ^a   Gigantino, Vincenzo ^c   Esposito, Pasquale ^a   Varricchi, Gilda ^a   Lambeau, Gerard ^d   Cassatella, Marco A ^e   Granata, Francescopaolo ^a   Marone, Gianni ^a,f  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

^e UNIVERSITY OF VERONA   (Italy)

^f CNR   (Italy)

Author keywords

Angiopoietin; Integrin; Lung tumor; Neutrophil; PLA2R1; Secreted phospholipase A2; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; INTERLEUKIN 8; PHOSPHOLIPASE A2 GROUP V; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; GENE EXPRESSION; HEPATITIS G; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; INFLAMMATION; ISOLATION AND PURIFICATION; LUNG CANCER; LUNG TUMOR; MEDIATOR RELEASE; NEOPLASM; NEUTROPHIL; PROANGIOFENIC FACTOR; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 85018452329     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00443     Document Type: Article

References (66)

1. Murakami M, Lambeau G. Emerging roles of secreted phospholipase A(2) enzymes: an update. Biochimie (2013) 95:43-50. doi: 10.1016/j.biochi.2012.09.007
2. Bernard D, Vindrieux D. PLA2R1: expression and function in cancer. Biochim Biophys Acta (2014) 1846:40-4. doi:10.1016/j.bbcan.2014.03.003
3. Fujita M, Zhu K, Fujita CK, Zhao M, Lam KS, Kurth MJ, et al. Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins alphavbeta3, alpha4beta1, and alpha5beta1. J Biol Chem (2015) 290:259-71. doi:10.1074/jbc.M114.579946
4. Lambeau G, Ancian P, Barhanin J, Lazdunski M. Cloning and expression of a membrane receptor for secretory phospholipases A2. J Biol Chem (1994) 269:1575-8
5. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem (2008) 77:495-520. doi:10.1146/annurev.biochem.76.062405.154007
6. Lambeau G, Lazdunski M. Receptors for a growing family of secreted phospholipases A2. Trends Pharmacol Sci (1999) 20:162-70. doi:10.1016/S0165-6147(99)01300-0
7. Saegusa J, Akakura N, Wu CY, Hoogland C, Ma Z, Lam KS, et al. Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner. J Biol Chem (2008) 283:26107-15. doi:10.1074/jbc.M804835200
8. Kim KP, Rafter JD, Bittova L, Han SK, Snitko Y, Munoz NM, et al. Mechanism of human group V phospholipase A2 (PLA2)-induced leukotriene biosynthesis in human neutrophils. A potential role of heparan sulfate binding in PLA2 internalization and degradation. J Biol Chem (2001) 276:11126-34. doi:10.1074/jbc.M004604200
9. Boilard E, Bourgoin SG, Bernatchez C, Poubelle PE, Surette ME. Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans. FASEB J (2003) 17:1068-80. doi:10.1096/fj.02-0938com
10. Murakami M, Taketomi Y, Miki Y, Sato H, Hirabayashi T, Yamamoto K, et al. Recent progress in phospholipase A(2) research: from cells to animals to humans. Prog Lipid Res (2011) 50:152-92. doi:10.1016/j.plipres.2010.12.001
11. Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev (2011) 111:6130-85. doi:10.1021/cr200085w
12. Menschikowski M, Hagelgans A, Nacke B, Jandeck C, Mareninova OA, Asatryan L, et al. Epigenetic control of group V phospholipase A2 expression in human malignant cells. Tumour Biol (2016) 37:8097-105. doi:10.1007/s13277-015-4670-x
13. Brglez V, Lambeau G, Petan T. Secreted phospholipases A2 in cancer: diverse mechanisms of action. Biochimie (2014) 107(Pt A):114-23. doi:10.1016/j.biochi.2014.09.023
14. Laye JP, Gill JH. Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discov Today (2003) 8:710-6. doi:10.1016/S1359-6446(03)02754-5
15. Scott KF, Sajinovic M, Hein J, Nixdorf S, Galettis P, Liauw W, et al. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie (2010) 92:601-10. doi:10.1016/j.biochi.2010.03.019
16. Degousee N, Ghomashchi F, Stefanski E, Singer A, Smart BP, Borregaard N, et al. Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem (2002) 277:5061-73. doi:10.1074/jbc.M109083200
17. Granata F, Frattini A, Loffredo S, Del Prete A, Sozzani S, Marone G, et al. Signaling events involved in cytokine and chemokine production induced by secretory phospholipase A2 in human lung macrophages. Eur J Immunol (2006) 36:1938-50. doi:10.1002/eji.200535567
18. Granata F, Frattini A, Loffredo S, Staiano RI, Petraroli A, Ribatti D, et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol (2010) 184:5232-41. doi:10.4049/jimmunol.0902501
19. Solodkin-Szaingurten I, Levy R, Hadad N. Differential behavior of sPLA2-V and sPLA2-X in human neutrophils. Biochim Biophys Acta (2007) 1771:155-63. doi:10.1016/j.bbalip.2006.11.013
20. Triggiani M, Giannattasio G, Calabrese C, Loffredo S, Granata F, Fiorello A, et al. Lung mast cells are a source of secreted phospholipases A2. J Allergy Clin Immunol (2009) 124:558-65, 565.e1-3. doi:10.1016/j.jaci.2009.04.035
21. Triggiani M, Granata F, Frattini A, Marone G. Activation of human inflammatory cells by secreted phospholipases A2. Biochim Biophys Acta (2006) 1761:1289-300. doi:10.1016/j.bbalip.2006.07.003
22. Jo EJ, Lee HY, Lee YN, Kim JI, Kang HK, Park DW, et al. Group IB secretory phospholipase A2 stimulates CXC chemokine ligand 8 production via ERK and NF-kappa B in human neutrophils. J Immunol (2004) 173:6433-9. doi:10.4049/jimmunol.173.10.6433
23. Silliman CC, Moore EE, Zallen G, Gonzalez R, Johnson JL, Elzi DJ, et al. Presence of the M-type sPLA(2) receptor on neutrophils and its role in elastase release and adhesion. Am J Physiol Cell Physiol (2002) 283:C1102-13. doi:10.1152/ajpcell.00608.2001
24. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol (2011) 11:519-31. doi:10.1038/nri3024
25. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 16:183-94. doi:10.1016/j.ccr.2009.06.017
26. Mantovani A. The yin-yang of tumor-associated neutrophils. Cancer Cell (2009) 16:173-4. doi:10.1016/j.ccr.2009.08.014
27. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol (2013) 23:200-7. doi:10.1016/j.semcancer.2013.02.001
28. Galdiero MR, Bianchi P, Grizzi F, Di Caro G, Basso G, Ponzetta A, et al. Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer. Int J Cancer (2016) 139:446-56. doi:10.1002/ijc.30076
29. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol (2009) 27:4709-17. doi:10.1200/JCO.2008.18.9498
30. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol (2011) 54:948-55. doi:10.1016/j.jhep.2010.08.041
31. Rao HL, Chen JW, Li M, Xiao YB, Fu J, Zeng YX, et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis. PLoS One (2012) 7:e30806. doi:10.1371/journal.pone.0030806
32. Trellakis S, Bruderek K, Dumitru CA, Gholaman H, Gu X, Bankfalvi A, et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int J Cancer (2011) 129:2183-93. doi:10.1002/ijc.25892
33. Wislez M, Rabbe N, Marchal J, Milleron B, Crestani B, Mayaud C, et al. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res (2003) 63:1405-12
34. Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest (2014) 124:5466-80. doi:10.1172/JCI77053
35. Saha S, Biswas SK. Tumor-associated neutrophils show phenotypic and functional divergence in human lung cancer. Cancer Cell (2016) 30:11-3. doi:10.1016/j.ccell.2016.06.016
36. Tecchio C, Cassatella MA. Neutrophil-derived cytokines involved in physiological and pathological angiogenesis. Chem Immunol Allergy (2014) 99:123-37. doi:10.1159/000353358
37. Marone G, Granata F. Angiogenesis, lymphangiogenesis and clinical implications. preface. Chem Immunol Allergy (2014) 99:XI-XII. doi:10.1159/000352074
38. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG, et al. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer (2014) 14:159-72. doi:10.1038/nrc3677
39. Carmeliet P. Angiogenesis in health and disease. Nat Med (2003) 9:653-60. doi:10.1038/nm0603-653
40. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med (2003) 9:669-76. doi:10.1038/nm0603-669
41. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A (1996) 93:2576-81. doi:10.1073/pnas.93.6.2576
42. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res (2002) 62:4123-31
43. Bates DO, Mavrou A, Qiu Y, Carter JG, Hamdollah-Zadeh M, Barratt S, et al. Detection of VEGF-A(xxx)b isoforms in human tissues. PLoS One (2013) 8:e68399. doi:10.1371/journal.pone.0068399
44. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer (2008) 8:880-7. doi:10.1038/nrc2505
45. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell (1996) 87:1161-9. doi:10.1016/S0092-8674(00)81812-7
46. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 277:55-60. doi:10.1126/science.277.5322.55
47. Marone G, Varricchi G, Loffredo S, Granata F. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. Eur J Pharmacol (2015) 778:146-51. doi:10.1016/j.ejphar.2015.03.088
48. Loffredo S, Staiano RI, Granata F, Genovese A, Marone G. Immune cells as a source and target of angiogenic and lymphangiogenic factors. Chem Immunol Allergy (2014) 99:15-36. doi:10.1159/000353316
49. Gaudry M, Brégerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood (1997) 90:4153-61
50. Neagoe PE, Brkovic A, Hajjar F, Sirois MG. Expression and release of angiopoietin-1 from human neutrophils: intracellular mechanisms. Growth Factors (2009) 27:335-44. doi:10.3109/08977190903155043
51. Tecchio C, Scapini P, Pizzolo G, Cassatella MA. On the cytokines produced by human neutrophils in tumors. Semin Cancer Biol (2013) 23:159-70. doi:10.1016/j.semcancer.2013.02.004
52. Boilard E, Rouault M, Surrel F, Le Calvez C, Bezzine S, Singer A, et al. Secreted phospholipase A2 inhibitors are also potent blockers of binding to the M-type receptor. Biochemistry (2006) 45:13203-18. doi:10.1021/bi061376d
53. Granata F, Petraroli A, Boilard E, Bezzine S, Bollinger J, Del Vecchio L, et al. Activation of cytokine production by secreted phospholipase A2 in human lung macrophages expressing the M-type receptor. J Immunol (2005) 174:464-74
54. Johnston B, Kubes P. The alpha4-integrin: an alternative pathway for neutrophil recruitment? Immunol Today (1999) 20:545-50. doi:10.1016/S0167-5699(99)01544-3
55. Lawson MA, Maxfield FR. Ca(2+)-and calcineurin-dependent recycling of an integrin to the front of migrating neutrophils. Nature (1995) 377:75-9. doi:10.1038/377075a0
56. Cho W. Structure, function, and regulation of group V phospholipase A(2). Biochim Biophys Acta (2000) 1488:48-58. doi:10.1016/S1388-1981(00)00109-8
57. Choi Y, Kim E, Lee Y, Han MH, Kang IC. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin. Proteomics (2010) 10:72-80. doi:10.1002/pmic.200900146
58. Muro F, Iimura S, Sugimoto Y, Yoneda Y, Chiba J, Watanabe T, et al. Discovery of trans-4-[1-[[2,5-dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist. J Med Chem (2009) 52:7974-92. doi:10.1021/jm901154c
59. Oslund RC, Cermak N, Gelb MH. Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. J Med Chem (2008) 51:4708-14. doi:10.1021/jm800422v
60. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
61. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol (2013) 228:1404-12. doi:10.1002/jcp.24260
62. de Paulis A, Prevete N, Fiorentino I, Rossi FW, Staibano S, Montuori N, et al. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol (2006) 177:7322-31. doi:10.4049/jimmunol.177.10.7322
63. Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M. Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant. Trends Cardiovasc Med (2011) 21:204-10. doi:10.1016/j.tcm.2012.05.011
64. Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando-Randone S, Conforti ML, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res (2011) 109:e14-26. doi:10.1161/CIRCRESAHA.111.242057
65. Kikuchi R, Nakamura K, MacLauchlan S, Ngo DT, Shimizu I, Fuster JJ, et al. An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nat Med (2014) 20:1464-71. doi:10.1038/nm.3703
66. Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, Magnussen A, Schüler Y, Kelly SP, et al. Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur J Cancer (2008) 44:1883-94. doi:10.1016/j.ejca.2008.05.027